An observational study investigating the safety, tolerability and health outcomes of cannabinoid therapy prescribed to eligible patients for management of recognized chronic conditions

This is an observational, single center investigator driven study conducted in Australia with patients who are about to start cannabinoid therapy for management of recognized chronic conditions. Patients are to be enrolled into the study no earlier than their Physician’s decision to initiate treatment with a cannabinoid therapy. It is mandatory that the prescriber’s decision to start treatment with cannabinoid therapy was taken independently and before presenting the patient the option to participate in the study. Participants will be followed monthly for a maximum of 12 months from the signing of the informed consent forms (PISCF) or until death, withdrawal of consent, loss of follow-up/record, whichever comes first. During the follow-up visits, assessments will be performed according to routine local clinical practice. Data collected at each visit for the study may include: - Change in concomitant medications and rationale - Kessler Psychological Distress Scale (K10) score - Insomnia Severity Index score - Simple Pain Index score - Kemp Quality of Life Scale score - Rationale for change in cannabinoid therapy and/or dose if applicable - Participant withdrawal from the study and/or reason for discontinuation of cannabinoid therapy - Adverse Events/Serious Adverse Events/Adverse Drug reaction that may have occurred while on the study Follow-up patient reports detailing the required information will be completed for a maximum of 12 months (Reports to coincide with patient visit for follow-up consultation and/or new cannabinoid therapy prescription).